echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Science News > Reactivate the "paralyzed" immune system to attack deadly brain cancer

    Reactivate the "paralyzed" immune system to attack deadly brain cancer

    • Last Update: 2021-07-06
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit

    Glioma is the most common primary central nervous system tumor.
    Because it has no clear boundary with normal brain tissue, it is difficult to completely remove, so it is not very sensitive to radiotherapy and chemotherapy, and it is very easy to recur, and there is no effective response.


    To solve this problem, scientists are trying to find innovative treatments that use the immune system to fight gliomas through therapeutic vaccines or immunotherapy, so that cancer patients who have no cures can benefit as soon as possible

    Recently, researchers from research institutions such as the German Cancer Research Center (DKFZ), the University of Freiburg Medical Center, and the Mannheim School of Medicine of Heidelberg University have jointly published an article titled Tryptophan me in the top academic journal "Nature Cancer".
    tabolism drives dynamic immunosuppressive myeloid states in IDH-mutant gliomas article

    This study found that glioma cells can reprogram and invade immune cells through a common mutation, thereby "paralyzing" the body's immune defense against tumors
    To this end, researchers have developed an innovative treatment to reactivate the "paralyzed" immune system against tumors, that is, to fight gliomas through therapeutic vaccines or immunotherapy


    Interestingly, gliomas are not entirely composed of cancer cells.
    Up to 50% of tumor masses are composed of microglia and monocyte-derived macrophages.
    Here we collectively refer to them as glioma-related Myeloid cells (GAM)

    However, although macrophages are often referred to as "cell scavengers", they are "weak-hearted" in the face of gliomas and are not their opponents at all


    To this end, researchers began to look for other breakthroughs to combat glioma
    And I have a keen interest in the detection of the mutated gene "isocitrate dehydrogenase (IDH)" in 70% of gliomas


    Researchers have discovered that isocitrate dehydrogenase (IDH) mutations can cause glioma cells to release tumorigenic (R)-2-hydroxyglutarate (R-2-HG), which inhibits the immune system and T cell activity.
    The invading macrophages are reprogrammed, blocking the immune response of the tumor, and causing serious "immune paralysis", which can easily escape the pursuit of the human immune system


    But what makes glioma cells so rampant?

    To find out, the researchers deciphered the molecular mechanism by which R-2-HG reprograms macrophages
    The study found that it was the cancer-promoting metabolite R-2-HG that interfered with the amino acid metabolism of "cell scavenger" macrophages, and activated the central immune system regulatory molecule aryl hydrocarbon receptor (AHR), thereby causing macrophages to produce Immunosuppressive response


    Therefore, in view of the negative core role of aryl hydrocarbon receptors, the researchers decided to terminate the function of this key molecule in order to activate the paralyzed immune system
    Researchers combined T cell activation immunotherapy with immune checkpoint blocking and small molecule AHR inhibitors in animal models and found that the therapy can effectively extend the lifespan of mice with IDH mutant tumors

    (Biological Exploration)

    Note: The original text has been deleted

    Reference materials:



    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.
    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.